Branched-chain-ketoacid dehydrogenase (BCKDH) Gene Mutation Analysis
The BCKDH genes encode for an enzyme complex called branched-chain α-ketoacid dehydrogenase (BCKDH). This enzyme complex is composed of four subunits: E1α, E1β, E2, and E3. BCKDHA (cytogenetic location: 19q13.2) and BCKDHB (cytogenetic location: 6q14.1) genes respectively encode α and β submits of the complex. The DBT gene (cytogenetic location: 1q21.2) encodes the E2 component (dihydrolipoamide branched chain transacylase E2). The complex requires NAD, FAD, coenzyme A, lipoic acid and thiamin pyrophosphate (TPP) as cofactors and is involved in the oxidative decarboxylation of branched-chain amino acids (leucine, valine, and isoleucine).
A defect in any component of the BCKDH complex causes maple syrup urine disease (MSUD). MSUD is an autosomal recessive disorder with an incidence of approximately 1:200,000 live births, however, the disorder is very frequent in the Mennonite population with an estimated incidence of 1:378 live births. More than 80 mutations in the BCKDHA gene, 90 mutations in the BCKDHB gene and 70 mutations in the DBT gene have been identified. There are four distinct phenotypes of this disease, depending on the clinical presentation and severity of the mutations: (1) the classic form, which is the most severe and is characterized by very high plasma level of branched-chain amino acids; (2) thiamin-responsive form, in which clinical outcome improves with the administration of thiamin; (3) intermediate or intermittent form, which is triggered by high consumption of proteins; and (4) E3 deficiency, which is also associated with deficiencies of pyruvate dehydrogenase and α-ketoglutarate dehydrogenase.
Mutation in BCKDHA and BCKDHB genes are typically associated with severe, classic form of the disease which manifests within 24 hours after birth. Most BCKDHA mutations (MSUD, Type 1A) result in single amino acid substitutions in the alpha subunit of the enzyme complex. In the Mennonite population, the common mutation of the alpha subunit is associated with the replacement of tyrosine by asparagine at position 438 (Try438Asn or Y438N). Most BCKDHB mutations (MSUD, Type 1B) are missense mutations within the beta subunit of the enzyme complex although insertions and deletions have also been identified. Ashkenazi Jewish populations have a relatively high incidence (1 in 50,000 births) of this BCKDBH mutations. Over 99% of pathological variants in this population are missense mutations including: R183P (c.548G>C), G278S (c.832G>A), and E372X (c.1114G>T).
In these severe forms (MSUD, Type 1A and 1B), the activity of BCKDH complex is severely impaired resulting in the accumulation of branched-chain amino acids and their corresponding α-keto acids. Excessive excretion of these α-keto acids in urine give it the characteristic maple syrup-like odor, for which the disease is named. Clinically MSUD is characterized by feeding problems, failure to thrive, vomiting, lethargy. ketoacidosis, and change in muscular tone. Excessive accumulation of these amino acids and their derivatives can cause cerebral edema resulting in neurological symptoms, seizures, and coma. The disease is typically fatal if untreated and delayed treatment can lead to intellectual disability.
Mutations in the DBT gene include missense mutations as well as small insertions or deletions. These mutations result in mild variants of the disorder. Clinically onset of symptoms appears later in infancy or childhood although they are associated with delayed development and neurological manifestations if not treated. The symptoms can be worsened by increase protein intake and if the patient is under catabolic stress. Early diagnosis of MSUD is critical for the effective management of the disease, therefore virtually all newborn screening programs in the U.S. include screening for MSUD.
- Aid in the diagnosis of maple syrup urine disease (MSUD)
- Carrier screening in high-risk populations (Mennonite and Ashkenazi Jewish) or in individuals with family history of MUSD
- Prenatal diagnosis of MSUD in the couples at risk
- Any heterozygous mutations in one or more genes (BCKDHA, BCKDHB, DBT, and DLD) might indicate carrier status
- Compound heterozygous or homozygous mutations in one or more of these genes BCKDHA, BCKDHB, DBT, and DLD might be diagnostic for the disease
- If either of most common mutations such as R183P (c.548G>C), G278S (c.832G>A), and E372X (c.1114G>T) are present in BCKDH enzyme complex is consistent with Maple Syrup Urine Disease
Negative for mutations analyzed (No pathogenic variants detected)
Whole blood (EDTA), Amniotic fluid, Amniocyte culture, Dissected chorionic villus biopsy.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Am J Hum Genet. 2001;69(4):863-8. [PMID: 11509994]
- Am J Hum Genet. 2001;68(1):232-7. [PMID: 11112664]
- J Inherit Metab Dis. 1992;15(5):827-33. [PMID: 1434524]
- GeneReviews. Maple Syrup Urine Disease [PMID: 20301495]
- Front Biosci. 1998;3:d517–24 [PMID: 9609836]
- Pasquali M, Longo N. Newborn screening and inborn error of metabolism. In Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. 2018. Page 1698 – 1730.